Answers are grounded in this paper and cite their sources.
Patients with malignancy are vulnerable and inclined to invasive fungal infections (IFIs). The incidence of invasive fungal infection increases with the severity and duration of neutropenia. IFI is rarely seen in patients undergoing chemotherapy with a low myelotoxic risk, as in the treatment of solid tumors. Invasive aspergillosis (IA) is mortal and common in patients with hematological malignancies or hematopoietic stem cell transplantation due to severe neutropenia or immunosuppression [1]. IA is a mortal and relapsing infection in those patients group. Primary prophylaxis is implemented to prevent IA before occurring IA. Seconder prophylaxis is implemented to prevent relapsing of previous IA [2]. Fluconazole, itraconazole, amphotericin B, posaconazole, voriconazole, micafungin were reported to be used for prophylaxis in patients with hematological malignancies [3,4].
No takes yet. Share an insight, caveat, or question.
Habip Gedık (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: